For research use only. PeptaBase is for informational and laboratory research reference only. No medical claims are made and nothing on this site is intended to diagnose, treat, cure or prevent any disease.
PeptaBase
✓500+ PubMed Citations✓Free To Use✓No Account Required
Back to Database
Metabolic

AOD-9604 Protocol

Dosing & Research

Last Updated: September 4, 2026

Chemical Identity
Amino Acid Sequence
Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe
Molecular Formula
C78H123N23O23S2
Molecular Weight
1815.1 g/mol
CAS Number
221231-10-3

Body-composition studies, Lipolysis and adipocyte biology, Metabolic syndrome models, Weight-management research

Evidence Level
Mixed Evidence
Species Studied
Human • Rat • Mouse
Half-Life
~30 Minutes
Administration
Subcutaneous
Frequency
Once Or Twice Daily, Fasted

How It Works

  • Body-composition studies
  • Lipolysis and adipocyte biology
  • Metabolic syndrome models
  • Weight-management research

Dosing Structure

Dose
300 mcg daily (or 250 mcg BID)
Frequency
Once Or Twice Daily, Fasted
Notes
1x Daily: 300-600mcg taken first thing in the morning, fasted. 2x Daily: 250mcg taken directly before bed and first thing in the morning, fasted. Inject: Abdomen, thigh. AOD-9604 should be reconstituted with a mix of Bacteriostatic Water and Acetic Acid to prevent gelling (2.5ml/0.5ml BAC to AA recommended). Break: 1-2 months between cycles.

Example Protocols

Dose: 300 mcg daily (or 250 mcg BID)
Frequency: Once Or Twice Daily, Fasted
Duration: 4-8 weeks
Off Period: Not listed
Calculate dosing →

Find Research Grade AOD-9604

Recommended vendors for sourcing research-grade material. PeptaBase does not sell peptides directly.

Vendor One Research Labs

COA Verified

Third-party COA-verified research peptides with published batch testing.

Source Coming Soon

Vendor Two Sciences

Purity Tested

US-based research compound supplier with independent purity testing.

Source Coming Soon

Vendor Three Peptide Co.

Bulk research peptide sourcing with batch-level documentation.

Source Coming Soon
View all recommended vendors →

Protocol Notes

•
1x Daily: 300-600mcg taken first thing in the morning, fasted.
•
2x Daily: 250mcg taken directly before bed and first thing in the morning, fasted.
•
Inject: Abdomen, thigh.
•
AOD-9604 should be reconstituted with a mix of Bacteriostatic Water and Acetic Acid to prevent gelling (2.5ml/0.5ml BAC to AA recommended).
•
Break: 1-2 months between cycles.

What Is AOD-9604?

AOD-9604 is a modified fragment of human growth hormone (hGH 177-191) that was developed to isolate the fat-burning properties of GH without its growth-promoting or insulin-desensitizing effects. It completed Phase 3 clinical trials for obesity in Australia but did not receive regulatory approval. Researchers study it as a lipolytic compound that activates beta-adrenergic pathways and inhibits lipogenesis.

Research Observations - Not Medical Claims
  • ▸Phase 3 obesity trial (METAOD study): AOD-9604 did not achieve statistically significant weight loss vs. placebo in the primary endpoint of the Phase 3 trial - the main reason it was not approved for obesity (PMID: 16413786).
  • ▸Lipolysis mechanism: AOD-9604 mimics the lipolytic action of hGH - it activates beta-3-adrenergic receptors in adipose tissue and inhibits acetyl-CoA carboxylase, the rate-limiting enzyme in de novo lipogenesis (PMID: 11600718).
  • ▸No IGF-1 effect: Unlike full-length GH, AOD-9604 does not stimulate IGF-1 production or promote anabolic tissue growth - important safety differentiation in long-term use.
  • ▸No glucose disturbance: Rodent studies confirmed AOD-9604 does not impair glucose tolerance or insulin sensitivity - a key advantage over full-length GH.
  • ▸Cartilage repair: Surprising finding - AOD-9604 showed regenerative effects on cartilage in in vitro and animal models; this has driven interest as a potential OA treatment (PMID: 24403479).

Evidence Summary

Mixed EvidenceFailed Phase 3 - not approved by any regulatory authority; Research Chemical
Evidence StrengthPreliminary
PreliminaryModerateStrong
Curated Citations3
Largest Study (n)300
Most Recent Study2023
Species Studied
HumanRatMouse

Commonly Researched With

Ipamorelin
GH secretagogues are studied alongside AOD-9604 in body composition research - ipamorelin for GH pulse amplification, AOD-9604 for isolated lipolysis.
CJC-1295
CJC-1295 increases GH/IGF-1; AOD-9604 provides the fat-loss action without IGF-1 elevation - combined in body recomposition protocols.
Tirzepatide
GLP-1/GIP agonists and AOD-9604 are studied for additive fat reduction through different mechanisms (central appetite vs. peripheral lipolysis).

Research & Studies

Loading citations…

Research Feedback

0 approved

For research discussion only. Community feedback is moderated and shown here as aggregated insights after approval.

Related Peptides

5 Amino 1 MQ
Metabolic
AICAR
Metabolic
Cagrilintide
Metabolic
Calcitonin
Metabolic